Drug Development | CHOP Research Institute
 

Drug Development

Published on
Jan 14, 2025
In a preclinical model, the team reversed symptoms of X-linked sideroblastic anemia, a rare disorder.
Published on
Jan 6, 2025
The CHOP-led trial showed that blinatumomab plus chemotherapy drastically improved survival rates for patients with B-ALL.
Published on
Dec 30, 2024
We tallied up the most popular Cornerstone blog stories of 2024 based on data across our CHOP Research social media platforms.
Published on
Dec 19, 2024
As the pediatric cancer charity celebrates its 20th anniversary, Cornerstone is highlighting the groundbreaking research at CHOP fueled by two decades of collaboration.
Published on
Sep 19, 2024
CHOP researchers developed a factor VIII variant that led to safe and long-lasting therapeutic results in preclinical models.
Published on
May 29, 2024
Decades ago, Katherine A. High, MD, and colleagues began an unprecedented journey to develop a new kind of treatment for hemophilia B.
Published on
Mar 5, 2024
Two global teams are developing solid cancer drugs and understanding T-cell receptors.

The mission of the Clinical Pharmacology RAG is to support CHOP investigators engaged in clinical pharmacology research, foster collaborations within the CHOP/Penn research community, and create additional educational opportunities for trainees.

Published on
Oct 11, 2023
The Center for Precision Medicine for High-risk Pediatric Cancer Frontier Program builds upon ongoing precision medicine efforts across CHOP departments to define and expand treatment options.
Published on
Sep 22, 2023
Dr. Patrick Grohar will lead a research team to bring new therapies to clinical trial.